Breast Cancer Product Details

Fruquintinib Capsules

Model: Manufacturer
|
Category: Oncology
HUTCHMED (Suzhou) Co., Ltd

Quick Info

Colorectal cancer, endometrial cancer

Description
Specification Features
Dosage Administration
Faqs

As monotherapy is indicated for patients with metastatic colorectal cancer (mCRC) who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable for receiving anti-vascular endothelial growth factor (VEGF) therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type).

1mg and 5 mg capsules

The recommended dose is 5mg once daily, for three consecutive weeks followed by one week of drug free period (Every 4 weeks as one treatment cycle).

This product may be taken with food or on empty stomach, and it must be swallowed whole. It is recommended to take the drug at the same time each day. If the patient vomits after administering the drug, there is no need to make up for the dose; if a dose is missed, instruct the patient not to make up for the dose in the next day, but to take the next dose at its next scheduled time.

The common (incidence ≥ 2%) Grade ≥3 adverse drug reactions were hypertension, hand-foot skin reaction, proteinuria, platelet count decreased, hepatic function abnormal, blood bilirubin increased, abdominal pain/abdominal discomfort, diarrhoea, fatigue/asthenia, decreased appetite and haemorrhage.

×